Genmab A/S ADS GMAB
i
Market datapartial · fetched 2026-11-06T21:46:03.890Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:09.67615217Z
FundamentalsAlpha Vantage · unavailable
Genmab A/S ADS options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 59.04 | 50.8% | 11.2% | 48.93 | 56.5% | 10.1% |
| 25Δ | 58.10 | 49.8% | 9.8% | 50.15 | 55.6% | 8.2% |
| 30Δ | 57.16 | 48.9% | 8.4% | 50.87 | 54.1% | 7.3% |
| 35Δ | 56.22 | 47.9% | 7.0% | 51.58 | 52.5% | 6.5% |
| 40Δ | 55.29 | 47.0% | 5.6% | 52.30 | 51.0% | 5.6% |
| 45Δ | 54.42 | 49.6% | 4.9% | 53.01 | 49.4% | 4.7% |
| 50Δ | 53.60 | 53.9% | 4.5% | 53.73 | 47.9% | 3.9% |
| 55Δ | 52.77 | 58.2% | 4.1% | 54.44 | 46.3% | 3.0% |
| 60Δ | 51.94 | 62.5% | 3.7% | 55.22 | 45.4% | 2.3% |
| 65Δ | 51.11 | 66.8% | 3.4% | 56.18 | 46.9% | 1.9% |
| 70Δ | 50.28 | 71.1% | 3.0% | 57.15 | 48.3% | 1.6% |
| 75Δ | 49.32 | 70.1% | 2.5% | 58.12 | 49.8% | 1.3% |
| 80Δ | 48.28 | 66.3% | 2.0% | 59.09 | 51.2% | 0.9% |
20Δ
- Pseudo strike
- 59.04
- IV
- 50.8%
- B/E move
- 11.2%
- Pseudo strike
- 48.93
- IV
- 56.5%
- B/E move
- 10.1%
25Δ
- Pseudo strike
- 58.10
- IV
- 49.8%
- B/E move
- 9.8%
- Pseudo strike
- 50.15
- IV
- 55.6%
- B/E move
- 8.2%
30Δ
- Pseudo strike
- 57.16
- IV
- 48.9%
- B/E move
- 8.4%
- Pseudo strike
- 50.87
- IV
- 54.1%
- B/E move
- 7.3%
35Δ
- Pseudo strike
- 56.22
- IV
- 47.9%
- B/E move
- 7.0%
- Pseudo strike
- 51.58
- IV
- 52.5%
- B/E move
- 6.5%
40Δ
- Pseudo strike
- 55.29
- IV
- 47.0%
- B/E move
- 5.6%
- Pseudo strike
- 52.30
- IV
- 51.0%
- B/E move
- 5.6%
45Δ
- Pseudo strike
- 54.42
- IV
- 49.6%
- B/E move
- 4.9%
- Pseudo strike
- 53.01
- IV
- 49.4%
- B/E move
- 4.7%
50Δ
- Pseudo strike
- 53.60
- IV
- 53.9%
- B/E move
- 4.5%
- Pseudo strike
- 53.73
- IV
- 47.9%
- B/E move
- 3.9%
55Δ
- Pseudo strike
- 52.77
- IV
- 58.2%
- B/E move
- 4.1%
- Pseudo strike
- 54.44
- IV
- 46.3%
- B/E move
- 3.0%
60Δ
- Pseudo strike
- 51.94
- IV
- 62.5%
- B/E move
- 3.7%
- Pseudo strike
- 55.22
- IV
- 45.4%
- B/E move
- 2.3%
65Δ
- Pseudo strike
- 51.11
- IV
- 66.8%
- B/E move
- 3.4%
- Pseudo strike
- 56.18
- IV
- 46.9%
- B/E move
- 1.9%
70Δ
- Pseudo strike
- 50.28
- IV
- 71.1%
- B/E move
- 3.0%
- Pseudo strike
- 57.15
- IV
- 48.3%
- B/E move
- 1.6%
75Δ
- Pseudo strike
- 49.32
- IV
- 70.1%
- B/E move
- 2.5%
- Pseudo strike
- 58.12
- IV
- 49.8%
- B/E move
- 1.3%
80Δ
- Pseudo strike
- 48.28
- IV
- 66.3%
- B/E move
- 2.0%
- Pseudo strike
- 59.09
- IV
- 51.2%
- B/E move
- 0.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 54.20% | |
| 50.83% | |
| 54.12% | |
| 56.81% | |
| 54.39% | |
| 50.13% | |
| 49.00% | |
| 48.37% | |
| 43.26% | |
| 48.15% |
Biotechnology
GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive…
More →GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet…
More →GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in…
More →GYRE
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary…
More →HALO
Description unavailable
More →HELP
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health…
More →